Will FibroGen Stock Rebound After Positive Roxadustat Data? |
| September 01, 2021 | September 2021 Bond Updates |
|
The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a large sell-off in FGEN stock, especially after the company disclosed that safety analyses from a late-stage study of Roxadustat. |
| View more at: https://www.forbes.com/sites/greatspeculations/2021/09/01/will-fibrogen-stock-rebound-after-positive-roxadustat-data/ |
| Related News |